P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

Bibliographic Details
Main Authors:	Philippe Moreau, Aurore Perrot, Meletios A. Dimopoulos, Thomas Martin, Thierry Facon, Marcelo Eduardo Capra, Meral Beksac, Nicole Armstrong, Franck Dubin, Sandrine Macé, Marie-Laure Risse, Christina Tekle, Zandra Klippel, Paul Richardson
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970628.27700.c7

Similar Items

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES
by: Aurore Perrot, et al.
Published: (2023-08-01)

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
by: Thomas Martin, et al.
Published: (2023-05-01)

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
by: Thomas Martin, et al.
Published: (2023-09-01)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS
by: Ecenur Guder Arslan, et al.
Published: (2023-10-01)

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
by: Thierry Facon, et al.
Published: (2023-08-01)

LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
by: E Crusoe, et al.
Published: (2023-10-01)

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
by: Alexander Lesokhin, et al.
Published: (2023-05-01)

Revised international staging system allocation in the ICARIA‐MM study: Practical challenges and impact on outcome
by: Paul G. Richardson, et al.
Published: (2022-02-01)

Étienne Cabet e l'educazione in Icaria
by: Paolo Levrero
Published: (2017-03-01)

3,931 MENDAFTAR MASUK KE MENARA ILMU
by: MPRC, Pusat Media & Perhubungan Awam
Published: (2017)

Ildefonso Rodríguez. Coplas del amo. Icaria, 1997.
by: José Enrique Martínez Fernández
Published: (1999-12-01)

Isatuximab and Belantamab Mafodotin: A Primer to an Evolving Multiple Myeloma Landscape
by: Rebecca Gonzalez, et al.
Published: (2021-04-01)

The Speech of Nature in Lucretius' De Rerum Natura 3.931-71
by: Reinhardt, T
Published: (2002)

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL
by: E. K. Mai, et al.
Published: (2022-06-01)

Educational package of ISDN signalling protocol (recommendation Q.921-Q931) /
by: 199164 Saiful Bahari, et al.
Published: (1990)

Educational package of ISDN signalling protocol (recommendation Q.921-Q931)
by: 199164 Saiful Bahari
Published: (1990)

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
by: Enrique M. Ocio, et al.
Published: (2023-02-01)

Cuvintele lui Qohílt ben Dawíd [971-931 î. Ch.], regele Ierusalimului
by: Florin Lăiu
Published: (2015-07-01)

Cuvintele lui Qohílt ben Dawíd [971-931 î. Ch.], regele Ierusalimului
by: Florin Lăiu
Published: (2015-07-01)

P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS
by: H. Quach, et al.
Published: (2022-06-01)

6.901 / 3.172 / 16.652 / 6.931 Inventions and Patents, Fall 2003
by: Rines, Robert H.
Published: (2003)

Altiero Spinelli, Cómo traté de hacerme sabio, Barcelona, Icaria, 2019, 469 pp.
by: Paola Lo Cascio
Published: (2020-03-01)

Joan Nogué (ed.): Yi-fu Tuan. El arte de la geografía. Icaria, Espacios Críticos, Barcelona: Icaria (col. espacios críticos), 2018, 262 pp. ISBN. 978-84-9888-815-7.
by: Jesús Monteagudo López-Menchero
Published: (2018-12-01)

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset
by: Faouzi Djebbari, et al.
Published: (2022-06-01)

Calibration of 93.1GHz FOD detection radar on airport runway using trihedral corner reflector
by: Yusri, N. A., et al.
Published: (2021)

931 Augmenting antigen presentation to improve CD8+ and CD4+ T cell responses in lung cancer
by: Jason Schenkel, et al.
Published: (2023-11-01)

P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS
by: André Baruchel, et al.
Published: (2023-08-01)

Metallic cylinder reflected power measurement for 93.1GHz frequency modulated continuous wave radar calibration.
by: Ja’afar, P. N., et al.
Published: (2023)

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
by: Wee-Joo Chng, et al.
Published: (2023-01-01)

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients
by: Hoai‐Thu Thai, et al.
Published: (2023-12-01)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
by: Joshua Richter, et al.
Published: (2023-04-01)

EXTRAMEDULLARY DISEASE
by: Meral Beksac
Published: (2022-04-01)

P931: PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
by: G. Giuffrida, et al.
Published: (2022-06-01)

Afrahat, Mowa XXI: O prześladowaniu (Demonstratio XXI: De Persecutione, PSyr 1, 931-990) ܬܚܘܝܬܐ ܕܪܕܘܦܝܐ
by: Andrzej Uciecha
Published: (2021-09-01)

P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
by: F. B. Askeland, et al.
Published: (2022-06-01)

P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
by: Frida Bugge Askeland, et al.
Published: (2023-08-01)

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
by: David H. Vesole, et al.
Published: (2023-08-01)

Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg
by: Sigrid De Wilde, et al.
Published: (2023-12-01)

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma
by: Fatiha Rachedi, et al.
Published: (2022-06-01)

Characterization of radar cross section using trihedral corner reflector for 9.31ghz frequency modulated continuous wave radar /
by: Nur Aqilah Yusri, 1996-, author 653637, et al.
Published: (2024)